ImmunityBio Inc (NASDAQ:IBRX) shares are trading down after an early morning high on Friday after the company announced an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses produced, to supply ImmunityBio with Bacillus Calmette-Guerin (BCG).  Increasing the available supply of BCG is intended to address shortages for the combination therapy with Anktiva. The agreement covers the manufacturing of standard BCG (sBCG) that is currently approved for use outside the U.S., and a next-generation recombinant BCG (iBCG) undergoing testing, intended for use in combination with ImmunityBio’s Anktiva (nogapendekin alfa inbakicept-pmln) for currently approved and potential future indications. In April, ...